Alembic Pharmaceuticals Limited
APLLTD.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$157.44B
Close$
$371.24
53.5% downside
Current Fair Value
53.5% downsideOvervalued by 53.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $157.44 Billion |
|---|---|
| Enterprise Value | $157.44 Billion |
| Dividend Yield | $12.00 (1.50%) |
| Earnings per Share | $34.33 |
| Beta | 0.31 |
| Outstanding Shares | 196,563,124 |
Return
| Return on Equity | 12.23% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 22.71 |
|---|---|
| PEG | 187.58 |
| Price to Sales | 2.01 |
| Price to Book Ratio | 2.77 |
| Enterprise Value to Revenue | 2.02 |
| Enterprise Value to EBIT | 19.11 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$7.79
Average shareholder expectationRevenue Estimate
$18.81 B
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$11.00
Average shareholder expectationRevenue Estimate
$22.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alembic Pharmaceuticals Limited
17,244 employees
CEO: Chirayu Ramanbhai Amin Established in 1907 and headquartered in Vadodara, India, Alembic Pharmaceuticals is a company dedicated to the creation, production, and sale of a diverse range of medicinal goods. Its activities span both its home country of India and ...